Were Analysts Bullish Zogenix, Inc. (NASDAQ:ZGNX) This Week?

February 14, 2018 - By Michael Collier

 Were Analysts Bullish Zogenix, Inc. (NASDAQ:ZGNX) This Week?

Zogenix, Inc. (NASDAQ:ZGNX) Ratings Coverage

Among 7 analysts covering Zogenix (NASDAQ:ZGNX), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Zogenix had 15 analyst reports since August 6, 2015 according to SRatingsIntel. The company was upgraded on Thursday, August 6 by Zacks. As per Monday, October 2, the company rating was maintained by Leerink Swann. The rating was maintained by Brean Capital on Thursday, September 17 with “Buy”. The stock of Zogenix, Inc. (NASDAQ:ZGNX) has “Buy” rating given on Friday, September 29 by William Blair. The rating was maintained by Stifel Nicolaus with “Buy” on Friday, September 29. JMP Securities initiated Zogenix, Inc. (NASDAQ:ZGNX) on Monday, November 27 with “Buy” rating. On Tuesday, August 11 the stock rating was maintained by Leerink Swann with “Outperform”. The rating was maintained by Stifel Nicolaus on Monday, June 26 with “Buy”. The firm earned “Buy” rating on Thursday, September 21 by Stifel Nicolaus. The firm has “Hold” rating by Zacks given on Saturday, August 15. Below is a list of Zogenix, Inc. (NASDAQ:ZGNX) latest ratings and price target changes.

27/11/2017 Broker: JMP Securities Rating: Buy New Target: $56.0 Initiate
02/10/2017 Broker: Leerink Swann Old Rating: Outperform New Rating: Outperform Old Target: $20 New Target: $50 Maintain
29/09/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $55.0 Maintain
29/09/2017 Broker: William Blair Rating: Buy Upgrade
21/09/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $26.0 Maintain
06/09/2017 Broker: Mizuho Rating: Buy New Target: $28.0

The stock decreased 0.13% or $0.05 during the last trading session, reaching $38.05. About 352,282 shares traded. Zogenix, Inc. (NASDAQ:ZGNX) has risen 52.57% since February 14, 2017 and is uptrending. It has outperformed by 35.87% the S&P500.

Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. The company has market cap of $1.30 billion. The companyÂ’s lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. It currently has negative earnings. It also develops Relday, an injectable formulation of risperidone to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older.

More important recent Zogenix, Inc. (NASDAQ:ZGNX) news were published by: Globenewswire.com which released: “Zogenix to Participate in Leerink Partners 7th Annual Global Healthcare Conference” on February 08, 2018, also Globenewswire.com published article titled: “Zogenix Announces Receipt of FDA Breakthrough Therapy Designation for ZX008 in …”, Globenewswire.com published: “Zogenix Completes Enrollment in Second ZX008 Phase 3 Clinical Trial in Dravet …” on January 31, 2018. More interesting news about Zogenix, Inc. (NASDAQ:ZGNX) was released by: Prnewswire.com and their article: “Free Research Reports on these Drug Makers Stocks — Sanofi, Shire …” with publication date: February 13, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.